Results 21 to 30 of about 509,733 (375)

Climacteric Lowers Plasma Levels of Platelet-Derived Microparticles: A Pilot Study in Pre-versus Postmenopausal Women [PDF]

, 2012
Background: Climacteric increases the risk of thrombotic events by alteration of plasmatic coagulation. Up to now, less is known about changes in platelet-(PMP) and endothelial cell-derived microparticles (EMP). Methods: In this prospective study, plasma
Andreas Rank, Bal L, Berckmans RJ, Berckmans RJ, Bettina Toth, Biro E, Corada M, Cramer EM, Dratva J, Erhard Hiller, Faddy MJ, Flaumenhaft R, Gemmell CH, Giansante C, Gilbert GE, Horstman LL, Joop K, Katharina Nikolajek, Koga H, Kuriyama N, Li X, Miyazaki Y, Myers DD, Nagata Y, Nieuwland R, Nomura S, Rabe T, Ramacciotti E, Rank A, Rank A, Rectenwald JE, Rienk Nieuwland, Sabine Roesner, Sagripanti A, Simak J, Sims PJ, Stevens RF, Tan KT, Tarantino MD, Thiagarajan P, Toth B, Travlos GS, van der Zee PM, Warren BA   +43 more
core   +6 more sources

The international, prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention

Haematologica, 2015
Standard treatment for Glanzmann thrombasthenia, a severe inherited bleeding disorder, is platelet transfusion. Recombinant factor VIIa is reported to be effective in Glanzmann thrombasthenia with platelet antibodies and/or refractoriness to platelet ...
Man-Chiu Poon, Roseline d’Oiron, Rainer B. Zotz, Niels Bindslev, Matteo Nicola Dario Di Minno, Giovanni Di Minno   +5 more
doaj   +1 more source

Acquired factor V inhibitors in a polytraumatized patient [PDF]

Vojnosanitetski Pregled, 2005
Background. Factor V (FV) inhibitors are a rare disorder reported for the first time about fifty years ago, mostly with the unknown cause. The appearance of FV inhibitors is usually preceded by surgery, infections, administration of antibiotics or ...
Tukić Ljiljana, Stamatović Dragana, Tarabar Olivera, Elez Marija, Zorić Miodrag, Mandić-Radić Slavka   +5 more
doaj   +1 more source

Perinatal Gene Transfer to the Liver [PDF]

, 2011
The liver acts as a host to many functions hence raising the possibility that any one may be compromised by a single gene defect. Inherited or de novo mutations in these genes may result in relatively mild diseases or be so devastating that death within
Buckley, SM, Chan, JK, Howe, SJ, McKay, TR, Rahim, AA, Waddington, SN, Ward, NJ   +6 more
core   +1 more source

The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia

Haematologica, 2015
Standard treatment for Glanzmann thrombasthenia is platelet transfusion. Recombinant activated factor VII has been shown to be successful in patients with Glanzmann thrombasthenia with platelet antibodies or who are refractory to platelet transfusions ...
Giovanni Di Minno, Rainer B Zotz, Roseline d’Oiron, Niels Bindslev, Matteo Nicola Dario Di Minno, Man-Chiu Poon   +5 more
doaj   +1 more source

Inhibitors in Patients with Congenital Bleeding Disorders Other Than Hemophilia [PDF]

, 2017
The most worrying complication of replacement therapy for severe hemophilia A and B is currently the occurrence of inhibitory alloantibodies against infused factor VIII and factor IX, respectively.
Franchini, Massimo, Liumbruno, Giancarlo Maria, Marano, Giuseppe, Mengoli, Carlo, Piccinini, Vanessa, Pupella, Simonetta, Vaglio, Stefania   +6 more
core   +1 more source

The International Prospective Glanzmann Thrombasthenia Registry: Pediatric Treatment and Outcomes

TH Open, 2019
Background Standard treatment for Glanzmann thrombasthenia (GT), a severe inherited bleeding disorder, is platelet transfusion. Recombinant activated factor VII (rFVIIa) is reported to be effective in GT with platelet antibodies and/or refractoriness to ...
Rainer B. Zotz, Man-Chiu Poon, Giovanni Di Minno, Roseline D'Oiron   +3 more
doaj   +1 more source

Hemorheological Failure in the Pathology of Cardio-vascular Complications in Patients with Diabetic Foot Syndrome [PDF]

, 2016
The literature that includes the study of cardiovascular complications in patients with diabetic foot syndrome was analyzed. The topicality of this problem is caused by the steady growth of diabetes mellitus morbidity among people.
Кorobko, Е. (Еlina)
core   +2 more sources

New Blood Coagulation Factor XIIa Inhibitors: Molecular Modeling, Synthesis, and Experimental Confirmation

Molecules, 2022
In the modern world, complications caused by disorders in the blood coagulation system are found in almost all areas of medicine. Thus, the development of new, more advanced drugs that can prevent pathological conditions without disrupting normal ...
A. Tashchilova, Nadezhda Podoplelova, A. Sulimov, D. Kutov, I. Ilin, M. Panteleev, K. Shikhaliev, S. Medvedeva, N. Novichikhina, Andrey Potapov, Vladimir B Sulimov   +10 more
semanticscholar   +1 more source

Pathophysiology of Coagulation and Emerging Roles for Extracellular Vesicles in Coagulation Cascades and Disorders

Journal of Clinical Medicine, 2022
The notion of blood coagulation dates back to the ancient Greek civilization. However, the emergence of innovative scientific discoveries that started in the seventeenth century formulated the fundamentals of blood coagulation.
Houssam Al-Koussa, Ibrahim AlZaim, M. El-Sabban   +2 more
semanticscholar   +1 more source